September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Association of fluid recurrence with visual maintenance following the loading phase in anti-VEGF therapy for neovascular AMD
Author Affiliations & Notes
  • Sebastian M Waldstein
    Ophthalmology, Medical University of Vienna, Vienna, Austria
  • Victor Chong
    Opthalmology, Oxford Eye Hospital, Oxford, United Kingdom
  • Michael Larsen
    Rigshospitalet-Glostrup and University of Copenhagen, Copenhagen, Denmark
  • James Warburton
    Novartis Pharma AG, Basel, Switzerland
  • Andreas Weichselberger
    Novartis Pharma AG, Basel, Switzerland
  • Jonathan Wright
    Numerus Ltd, Wokingham, United Kingdom
  • Ursula Schmidt-Erfurth
    Ophthalmology, Medical University of Vienna, Vienna, Austria
  • Footnotes
    Commercial Relationships   Sebastian Waldstein, Bayer (C), Novartis (C); Victor Chong, Allergan (C), Allergan (F), Bayer (R), Novartis (C), Novartis (F), Quantel (C); Michael Larsen, Alcon (F), Allergan (F), Novartis (F), Roche (F); James Warburton, Novartis Pharma UK (E); Andreas Weichselberger, Novartis/Alcon (E); Jonathan Wright, Novartis Pharma UK (C); Ursula Schmidt-Erfurth, Alcon (C), Bayer (C), Boeringher Ingelheim GmbH (C), Novartis Pharma AG (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 533. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Sebastian M Waldstein, Victor Chong, Michael Larsen, James Warburton, Andreas Weichselberger, Jonathan Wright, Ursula Schmidt-Erfurth; Association of fluid recurrence with visual maintenance following the loading phase in anti-VEGF therapy for neovascular AMD. Invest. Ophthalmol. Vis. Sci. 2016;57(12):533.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Parameters such as baseline (BL) vision and certain lesion characteristics correlate with visual gain during anti-vascular endothelial growth factor (VEGF) therapy for neovascular age-related macular degeneration (nAMD). However, it is also important to understand individual differences in required treatment intensity to maintain this gain, which may allow treatment regimens to be individually customized. This study examined the association between specific courses of best corrected visual acuity (BCVA) development and fluid accumulation patterns on optical coherence tomography (OCT) after the completion of the loading phase of anti-VEGF therapy in nAMD patients.

Methods : Post-hoc analysis was performed on data from treatment-naïve nAMD patients enrolled in the EXCITE (n=353) and SUSTAIN (n=513) studies with fixed 12-weekly (q12) or PRN maintenance regimens after loading phase. Three groups were identified based on change in BCVA: 1) gain/maintain (BCVA change from BL–month M3 ≥0 and from M3–M12 ≥-5); 2) gain/loss (BCVA from BL–M3 ≥0 and BCVA from M3–M12 ≤-5); 3) no gain (BCVA from BL–M3 <0). Morphological parameters included presence of subretinal fluid (SRF) and intraretinal cystoid fluid (IRF). Fluid status at M4 (after the first treatment-free visit at M3) was compared between the groups.

Results : In EXCITE q12 patients (n=238), in the gain/maintain (n=98) and no gain (n=35) groups, IRF was stable after treatment discontinuation at M4 (IRF present in 14% of patients at M3 and 18% at M4; and 23% and 29%, respectively). In the gain/loss group (n=91), IRF presence increased significantly from M3 to M4 (from 13% at M3 to 37% at M4). New IRF at M4 was associated with decline in mean BCVA from M3 to M12 with this q12 regimen; increases in IRF later in the treatment period, i.e. at M5, were not associated with a BCVA decline. Loss of BCVA did not demonstrate strong associations with dynamic changes in SRF.

Conclusions : Declining BCVA after the loading phase with discontinuous anti-VEGF treatment was associated with an early increase in IRF, which suggests that patients with such fluid recurrence would likely benefit from more intensive treatment. Customizing individual treatment regimens in this manner may lessen the logistical burden which is increasingly evident in the treatment of nAMD.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×